Literature DB >> 27038812

Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas.

Simona Borsari1, Elena Pardi1, Natalia S Pellegata2, Misu Lee2, Federica Saponaro1, Liborio Torregrossa3, Fulvio Basolo3, Elena Paltrinieri1,4, Maria Chiara Zatelli5, Gabriele Materazzi3, Paolo Miccoli3, Claudio Marcocci1, Filomena Cetani6.   

Abstract

MEN1 is the main gene responsible for tumorigenesis of syndromic and sporadic primary hyperparathyroidism (PHPT). Germline mutations of the CDKN1B/p27Kip gene have been associated with multiple endocrine tumors in rats and humans. To evaluate the involvement of the CDKN1B gene and its relationship with MEN1 in sporadic PHPT, we carried out sequencing and loss of heterozygosity analyses of the CDKN1B gene in 147 sporadic parathyroid adenomas. p27 immunohistochemistry and genetic screening of the MEN1 gene were performed in 50 cases. Three germline CDKN1B variants (c.-80C>T, c.-29_-26delAGAG, c.397C>A) were identified in 3/147 patients. Reduction of CDKN1B gene transcription rate was demonstrated in vitro for the novel c.-80C>T and the c.-29_-26delAGAG variants. Loss of p27 expression was detected in the tumor carrying the c.-29_-26delAGAG variant. Two tumors carrying the CDKN1B variants also harbored a MEN1 mutation. Fifty-four percent of 50 CDKN1B mutation-negative tumors had a reduction of p27 nuclear staining. Somatic MEN1 mutations, identified in 15/50 samples, significantly segregated in tumors negative for nuclear and cytoplasmic p27 staining. The germline nature of the CDKN1B mutations suggests that they might predispose to PHPT. The lack of somatic CDKN1B mutations in our samples points to a rare involvement in parathyroid adenomas, despite the frequent loss of nuclear p27 expression. MEN1 biallelic inactivation seems to be directly related to down-regulation of p27 expression through the inhibition of CDKN1B gene transcription.

Entities:  

Keywords:  CDKN1B; MEN1-like; MEN4; Primary hyperparathyroidism

Mesh:

Substances:

Year:  2016        PMID: 27038812     DOI: 10.1007/s12020-016-0941-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  61 in total

Review 1.  Epigenetic alterations in human parathyroid tumors.

Authors:  Chiara Verdelli; Irene Forno; Valentina Vaira; Sabrina Corbetta
Journal:  Endocrine       Date:  2015-02-27       Impact factor: 3.633

2.  Mutations in CDKN2C (p18) and CDKN2D (p19) may cause sporadic parathyroid adenoma.

Authors:  Thomas Gluick; Ziqiang Yuan; Steven K Libutti; Stephen J Marx
Journal:  Endocr Relat Cancer       Date:  2013-11-06       Impact factor: 5.678

Review 3.  Molecular pathogenesis of primary hyperparathyroidism.

Authors:  F Cetani; E Pardi; S Borsari; C Marcocci
Journal:  J Endocrinol Invest       Date:  2011-07       Impact factor: 4.256

4.  Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.

Authors:  Donatella Malanga; Silvia De Gisi; Miriam Riccardi; Marianna Scrima; Carmela De Marco; Mercedes Robledo; Giuseppe Viglietto
Journal:  Eur J Endocrinol       Date:  2011-11-30       Impact factor: 6.664

Review 5.  Regulation of the cdk inhibitor p27 and its deregulation in cancer.

Authors:  J Slingerland; M Pagano
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

6.  Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese.

Authors:  C Tanaka; K Yoshimoto; S Yamada; H Nishioka; S Ii; M Moritani; T Yamaoka; M Itakura
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

7.  MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism.

Authors:  Maria Inês Alvelos; João Vinagre; Elsa Fonseca; Eva Barbosa; José Teixeira-Gomes; Manuel Sobrinho-Simões; Paula Soares
Journal:  Eur J Endocrinol       Date:  2012-12-31       Impact factor: 6.664

8.  Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Guiying Li; Allen B Choi; Andrew M Bellizzi; Thomas M O'Dorisio; James R Howe
Journal:  Cancer Genet       Date:  2015-09-15

9.  Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).

Authors:  Elena Pardi; Stefano Mariotti; Natalia S Pellegata; Katiuscia Benfini; Simona Borsari; Federica Saponaro; Liborio Torregrossa; Antonello Cappai; Chiara Satta; Marco Mastinu; Claudio Marcocci; Filomena Cetani
Journal:  Endocr Connect       Date:  2014-11-21       Impact factor: 3.335

Review 10.  MENX and MEN4.

Authors:  Natalia S Pellegata
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more
  9 in total

Review 1.  Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.

Authors:  Stephen J Marx; David Goltzman
Journal:  J Bone Miner Res       Date:  2018-12-10       Impact factor: 6.741

Review 2.  MEN4 and CDKN1B mutations: the latest of the MEN syndromes.

Authors:  Rami Alrezk; Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2017-08-19       Impact factor: 5.678

3.  Association between hypomagnesemia and severity of primary hyperparathyroidism: a retrospective study.

Authors:  Ding Na; Guo Tao; Liu Shu-Ying; Wang Qin-Yi; Qu Xiao-Li; Li Yong-Fang; Ou Yang-Na; Sheng Zhi-Feng; Yang Yan-Yi
Journal:  BMC Endocr Disord       Date:  2021-08-20       Impact factor: 2.763

Review 4.  Intratumor heterogeneity in human parathyroid tumors.

Authors:  C Verdelli; G S Tavanti; S Corbetta
Journal:  Histol Histopathol       Date:  2020-05-29       Impact factor: 2.303

5.  Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing's Disease With or Without an MEN4 Phenotype.

Authors:  Fanny Chasseloup; Nathan Pankratz; John Lane; Fabio R Faucz; Margaret F Keil; Prashant Chittiboina; Denise M Kay; Tara Hussein Tayeb; Constantine A Stratakis; James L Mills; Laura C Hernández-Ramírez
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 6.  Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.

Authors:  Martine Bocchini; Fabio Nicolini; Stefano Severi; Alberto Bongiovanni; Toni Ibrahim; Giorgia Simonetti; Ilaria Grassi; Massimiliano Mazza
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

Review 7.  Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice.

Authors:  C Christofer Juhlin; Lori A Erickson
Journal:  Endocr Pathol       Date:  2020-12-02       Impact factor: 3.943

8.  Association between Serum Magnesium and Hemoglobin in Patients with Primary Hyperparathyroidism.

Authors:  Na Ding; Tao Guo; Shu-Ying Liu; Qin-Yi Wang; Xiao-Li Qu; Yong-Fang Li; Yang-Na Ou; Yan-Yi Yang; Zhi-Feng Sheng
Journal:  Int J Endocrinol       Date:  2021-11-27       Impact factor: 3.257

Review 9.  Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management.

Authors:  Elisabetta Lavezzi; Alessandro Brunetti; Valeria Smiroldo; Gennaro Nappo; Vittorio Pedicini; Eleonora Vitali; Giampaolo Trivellin; Gherardo Mazziotti; Andrea Lania
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.